Latest news with #FluentInQuality
Yahoo
07-05-2025
- Business
- Yahoo
argenx SE (ARGX): A Bull Case Theory
We came across a bullish thesis on argenx SE (ARGX) on Substack by FluentInQuality. In this article, we will summarize the bulls' thesis on ARGX. argenx SE (ARGX)'s share was trading at $629.51 as of April 29th. ARGX's trailing and forward P/E were 49.26 and 90.91 respectively according to Yahoo Finance. Is Alzamend Neuro, Inc. (ALZN) the Cheapest Stock Insiders Are Buying In March? A biopharmaceutical facility with technicians working on a manufacturing line of treatments and preventions. argenx SE (ARGX) is emerging as a transformative force in the autoimmune space, not as a traditional biotech chasing one-off blockbuster drugs, but as a platform company methodically scaling a repeatable, high-leverage model. Its core strength lies in a single mechanism—FcRn inhibition—which is being deployed across a range of autoimmune conditions. The flagship therapy, Vyvgart, a first-in-class FcRn blocker, has already been approved for generalized myasthenia gravis (gMG), with promising expansion into chronic inflammatory demyelinating polyneuropathy (CIDP) and trials underway in autoimmune hematology, dermatology, and nephrology. This strategic expansion isn't random—it reflects a deliberate, pipeline-as-platform approach where each successful indication unlocks adjacent markets, accelerating scale and reach. What makes argenx particularly compelling is the chronic nature of the diseases it targets. Autoimmune conditions don't resolve; they require long-term management, translating into durable, recurring revenue. Vyvgart has already crossed €1 billion in annualized revenue, aided by the introduction of a subcutaneous formulation that enhances ease of access and adherence. As global rollout efforts continue across Europe, Japan, and China, and new indications come online, the addressable market keeps expanding. This isn't one-time therapy revenue—it's foundational, high-margin income in largely underserved, fragmented markets. Beyond Vyvgart, argenx is leveraging its FcRn-focused antibody platform to build a deep pipeline, including multiple efgartigimod variants targeting new autoimmune indications, with preclinical efforts also branching into oncology and nephrology. This diversification, grounded in a single, validated biological mechanism, reduces risk with each subsequent success. It's a textbook example of platform biotech, where discovery scale and efficiency create significant long-term optionality—far beyond the narrow view of being a 'single-asset' or 'rare disease' player. Financially, while current R&D investments remain substantial, they are the fuel driving platform expansion. As revenues scale, manufacturing efficiencies and global reach are set to unlock meaningful operating leverage. Argenx is now transitioning from the heavy investment phase to one where margins are expected to expand materially.
Yahoo
07-05-2025
- Business
- Yahoo
SAP SE (SAP): A Bull Case Theory
We came across a bullish thesis on SAP SE (SAP) on Substack by FluentInQuality. In this article, we will summarize the bulls' thesis on SAP. SAP SE (SAP)'s share was trading at $292.55 as of April 29th. SAP's trailing and forward P/E were 52.96 and 41.67 respectively according to Yahoo Finance. Nutanix, Inc. (NTNX): Among Louis Navellier's Stock Picks with Huge Upside Potential A close-up of a laptop screen displaying cloud platform application software. SAP SE (SAP) isn't flashy, but it's foundational—powering the global economy behind the scenes with software that acts less like a vendor and more like core infrastructure. With over 400,000 enterprises relying on SAP for mission-critical functions across manufacturing, logistics, finance, and HR, the company has embedded itself so deeply that switching providers is akin to changing an airplane engine mid-flight. Its ERP suite, led by S/4HANA, isn't simply a cloud migration—it's a full-scale operational rearchitecture. With over 25 vertical-specific modules and end-to-end integrations, SAP has transitioned into the real enterprise cloud story, not by chasing trends, but by delivering deeply embedded solutions tailored to the complexities of modern global businesses. This deep integration has created a customer base with unusually high stickiness, leading to a recurring cloud backlog that now accounts for more than 80% of total revenues. The result: once customers are on board, there's effectively no escape velocity. SAP's long-term pivot to the cloud is now bearing fruit. Cloud revenue is the fastest-growing segment, and as subscription models scale, gross margins are expanding. Operational efficiencies are surfacing, freeing capital for investment in high-leverage areas like artificial intelligence and R&D. Unlike companies using AI as a buzzword, SAP is embedding it strategically where it can generate tangible outcomes—automating invoice reconciliations, forecasting industrial demand, and driving ESG and procurement insights. SAP's AI isn't built for show—it's purpose-built for results. The company is steadily evolving from a legacy software giant into a lean, cloud-first platform focused on profitable compounding. The business case is further reinforced by SAP's handling of enterprise-scale problems. When global supply chains break, SAP is what holds them together. When compliance becomes a labyrinth, SAP untangles it. Its software addresses the kind of logic where failure isn't an inconvenience—it's a catastrophe. This ability to manage extreme complexity at scale, without compromising on performance or reliability, makes SAP indispensable.
